A diabetic foot ulcer that will not close is one of the most common reasons people with diabetes end up hospitalized, and in the worst cases, amputated. Roughly 19 to 34 percent of people with diabetes will develop a foot ulcer in their lifetime, and many of those wounds also come with nerve damage that leaves the area numb, slow to signal pain, and even slower to heal.
A new material described in the journal Bioactive Materials is aimed at both problems at once. Researchers built a hydrogel, a soft, water-based gel that can be applied directly to a wound, and loaded it with extracellular vesicles harvested from microalgae.
What is actually inside this gel
Extracellular vesicles are tiny, membrane-bound packages that cells release to communicate with each other. Human and animal cells produce them constantly, and in recent years scientists have found that vesicles from certain algae and plants carry a similar cargo of proteins, lipids, and genetic material that can influence nearby cells.
The appeal of using microalgae as the source is practical as much as biological. Algae can be grown at scale in tanks without the ethical and contamination concerns that come with harvesting vesicles from animal or human cells, and they produce compounds with strong antioxidant activity on their own.
The research team combined those algae-derived vesicles with a hydrogel base engineered to do two things simultaneously: neutralize excess oxidative stress at the wound site and calm the inflammatory response that keeps chronic diabetic wounds stuck in an unproductive loop.
Why diabetic wounds behave differently
In someone without diabetes, a cut moves through a fairly predictable sequence: bleeding stops, immune cells clear debris, new tissue forms, and the wound closes. High blood sugar disrupts nearly every step of that process.
Chronically elevated glucose damages small blood vessels, which reduces oxygen delivery to healing tissue. It also drives up production of reactive oxygen species, unstable molecules that damage cells and proteins faster than the body can repair them.
That excess oxidative stress keeps immune cells locked in an inflammatory state well past the point where they should be helping tissue rebuild. The wound essentially stalls in a holding pattern of inflammation and cell damage, which is why diabetic ulcers can remain open for months.
The nerve repair angle
What sets this study apart from typical wound-dressing research is the second target: peripheral nerve repair. Diabetic peripheral neuropathy, nerve damage caused by prolonged high blood sugar, affects roughly half of people with long-standing diabetes and often accompanies the same foot wounds the hydrogel is designed to treat.
Damaged peripheral nerves rely on Schwann cells, the support cells that wrap around nerve fibers and help them regenerate after injury. Oxidative stress and chronic inflammation impair Schwann cell function in the same way they impair skin healing, so a material that dampens both processes could theoretically support nerve regrowth alongside wound closure.
The study tested the hydrogel in diabetic models where both wound healing and nerve function were measured, rather than looking at skin closure in isolation. That combined approach reflects how diabetic foot complications actually present in patients, as intertwined vascular, immune, and nerve problems rather than a single isolated injury.
How the antioxidant and anti-inflammatory effects work together
The dual design matters because treating inflammation alone, without addressing oxidative stress, tends to produce incomplete results in diabetic tissue. Reactive oxygen species and inflammatory signaling feed each other in a cycle: oxidative damage triggers more immune activation, and that immune activation generates more reactive oxygen species.
By pairing the vesicles’ antioxidant cargo with a hydrogel matrix built to sustain anti-inflammatory activity over time, the researchers aimed to break that cycle at two points rather than one. This mirrors a broader trend in regenerative medicine, where single-mechanism treatments are increasingly being replaced by multi-target systems that address the several failure points chronic wounds share.
What this means for current treatment options
Standard care for diabetic foot ulcers today centers on wound debridement, offloading pressure from the affected area, infection control, and strict glucose management. Advanced dressings, growth factor therapies, and skin substitutes exist, but healing rates for chronic ulcers remain frustratingly inconsistent, and recurrence is common even after a wound closes.
A hydrogel that could plausibly speed healing while also supporting nerve function would address a gap that current dressings do not touch. Most wound-care products are designed to protect and moisten a wound, not to actively modulate the biology of nerve regeneration underneath it.
It is worth being precise about what the current evidence shows. This is a materials science and preclinical study, not a clinical trial in humans, and hydrogel formulations that perform well in early testing frequently require years of further development before they reach a pharmacy shelf or a wound clinic.
The broader shift toward algae-based biomaterials
This study is part of a growing body of work exploring algae, seaweed, and other marine organisms as sources of therapeutic compounds, an area sometimes grouped under the term blue biotechnology. Compared with mammalian cell sources, algae-derived vesicles are cheaper to produce at scale and carry a lower risk of triggering immune reactions or carrying pathogens.
That scalability is part of why extracellular vesicle research has moved so quickly from a niche cell-biology curiosity to a legitimate area of biomaterials engineering over the past several years. If algae-based vesicle production continues to prove reliable, it could lower one of the biggest barriers that has kept vesicle-based therapies largely confined to laboratories rather than clinics.
What comes next
The path from a promising hydrogel in a lab study to an approved wound-care product is long, and typically involves larger animal studies, safety and manufacturing standardization, and eventually controlled human trials. None of that has happened yet for this specific formulation.
What the study does establish is a proof of concept: that a single, relatively simple material, an injectable or applicable hydrogel loaded with algae-derived vesicles, can be engineered to address oxidative stress, inflammation, and nerve regeneration together rather than in isolation. For a complication as stubborn as the diabetic foot ulcer, treating those problems as connected rather than separate may turn out to be the more important insight than the algae itself.
